A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy

Completed · Phase 2

Conditions studied: Gaucher Disease, Type 1, Type 1 Gaucher Disease, Gaucher Disease

In brief

This study was conducted to test the safety and tolerability of afegostat tartrate in participants with type 1 Gaucher disease already receiving enzyme replacement therapy.

Key facts

Study ID

NCT00433147

Run by

Amicus Therapeutics

People needed

30

Starts

2007-03-23

Expected to finish

2008-02-19

Last updated by the study team

2018-09-25

Who can join

Age: 18 and older, up to 74. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Had a confirmed diagnosis of type 1 Gaucher disease with a known documented missense gene mutation in at least 1 of the 2 gene-encoding β-glucosidase alleles
• Clinically stable
• Male or female participants, 18 to 74 years old inclusive
• All participants of childbearing potential used adequate birth control
• Provided written informed consent to participate in the study

You may not qualify if…

• Clinically significant disease, severe complications from Gaucher disease, or serious illness that precluded participation in the study in the opinion of the Investigator that compromised the safety of the participant or precluded the participant from completing the study
• During the screening period, any clinically significant findings, as deemed by the Investigator
• Partial or total splenectomy (removal of spleen) within the 2 years prior to study entry
• History of pulmonary hypertension or Gaucher related lung disease
• History of allergy or sensitivity to the study drug or any excipients, including any prior serious adverse reaction to iminosugars (for example, N-butyldeoxynojirimycin or miglustat)
• Pregnant or breast-feeding
• Current/recent drug or alcohol abuse
• Treatment with any investigational product in the 90 days before study entry
• Treatment in the previous 90 days with any drug known to have a well-defined potential for toxicity to a major organ
• Presence or symptoms of gastrointestinal, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs

Where it is running

• Study site — San Francisco, California, United States
• Study site — Coral Springs, Florida, United States
• Study site — Decatur, Georgia, United States
• Study site — Iowa City, Iowa, United States
• Study site — New York, New York, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Portland, Oregon, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Pittsburgh, Pennsylvania, United States
• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.